| Expression pattern: |
UP |
| Associated gene: |
ADAM28 |
| Associated microRNA: |
miR-337-3p |
| Biological function: |
Promotes cisplatin resistance, proliferation and autophagy, inhibits apoptosis, and contributes to NSCLC tumor growth under DDP treatment. |
| Molecular mechanism: |
circRNA_100565 acts as a miR-337-3p sponge to indirectly up-regulate ADAM28, thereby regulating proliferation, apoptosis, autophagy and cisplatin resistance in NSCLC cells. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); autophagy (promotes); chemoresistance (promotes); ceRNA regulation (other) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Luciferase Reporter Assay; RNA Pull-Down; Transfection; CCK8; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circRNA_100565 expression was associated with shorter overall survival, lymph node metastasis and advanced TNM stages, and circRNA_100565 expression represented an independent prognostic factor in NSCLC. |
| Description: |
circRNA_100565 is up-regulated in NSCLC, especially in DDP-resistant tissues and cells, and high expression predicts poor overall survival. Functionally, circRNA_100565 promotes cisplatin resistance by enhancing proliferation and autophagy while suppressing apoptosis. Mechanistically, it acts through a circRNA_100565/miR-337-3p/ADAM28 axis and its knockdown increases DDP sensitivity in vitro and in xenograft tumors. |
| Confidence score: |
0.8586 |